Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition

Org. Biomol. Chem., 2020, Accepted Manuscript DOI: 10.1039/C9OB01190K, PaperDavid Goyard, B álint Kónya, Katalin Czifrák, Paolo Larini, Fanny Demontrond, Jeremy Leroy, Sophie Balzarin, Michel Tournier, Didier Tousch, Pierre Petit, Cedric Duret, Patrick Maurel, Tibor Docsa, Pal Gergely, László Somsák, jean-pierre praly, Jacqueline Azay-Milhau, Sebastien Vidal The design of glycogen phosphorylase (GP) inhibitors targeting the catalytic site of the enzyme is a promising strategy for a better control of hyperglycaemia in the context of type 2... The content of this RSS Feed (c) The Royal Society of Chemistry

Source: RSC - Organic and Biomolecular Chemistry - January 6, 2020 Category: Molecular Biology Authors: David Goyard Source Type: research